Poliovirus combined immunization with inactivated and live attenuated vaccines

  • H. Faden


Since the introduction of inactivated poliovirus vaccine in 1955 and live oral poliovirus vaccine in 1962, the number of cases of paralytic poliomyelitis has declined dramatically. In the United States, approximately five cases of poliomyelitis are reported annually and all of them are vaccine-associated. World-wide, there are approximately 200000 cases of natural poliomyelitis. Both the inactivated and live vaccines have proven to be highly effective. The disadvantages of inactivated vaccine are relatively poor mucosal immunity and a belief that booster doses are required to maintain immunity. Live oral vaccine, on the other hand, is associated with paralytic poliomyelitis and poor seroconversion rates in underdeveloped regions of the world. A new enhanced potency inactivated vaccine is more immunogenic, induces greater mucosal immunity, and requires less frequent boosting than earlier inactivated preparations. A sequentional immunization schedule consisting of two doses of enhanced potency inactivated vaccine followed by two doses of the live oral vaccine has been shown to induce excellent systemic and local immunity that is long lasting. The introduction of sequentional immunization as the schedule of choice will require additional simplification of a currently complex vaccine program for polio.


Mucosal Immunity Seroconversion Rate Local Immune Response Oral Poliovirus Vaccine Neutralize Antibody Titer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adenyi-Jones SC, Faden H, Ferdon MB, Kwong MS, Ogra PL (1992) Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 120: 686–689PubMedCrossRefGoogle Scholar
  2. 2.
    AndrusJK, de Quadros CA, Olive JM (1992) The Surveillance Challenge: Final Stages of Eradication of Poliomyelitis in the Americas, MMWR 41/no. SS-1: 21–26Google Scholar
  3. 3.
    Bodian D, Nathanson N (1960) Inhibitory effects of passive antibody on virulent poliovirus excretion and on immune response in chimpanzees. Bull Johns Hopkins Hosp 107: 143–162PubMedGoogle Scholar
  4. 4.
    Bottiger M (1987) A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 19: 595–601PubMedCrossRefGoogle Scholar
  5. 5.
    Christodoulose C, Colbere-Garapin G, Macadam A (1990) Mapping of mutations asso ciated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 64: 4922–4929Google Scholar
  6. 6.
    Dhar R, Ogra PL (1985) Local immune responses. Br Med Bull 41: 28–33PubMedGoogle Scholar
  7. 7.
    Dick GWA, Dane DS, McAlister J, Briggs M, Nelson R, Field CMB (1961) Vaccination against poliomyelitis with live virus vaccines. Brit Med J 266–269Google Scholar
  8. 8.
    Domok L, Balayna MS, Fayinka OA, Skrtic N, Soneji AD, Harland PSEG (xxx) Factors affecting the efficacy of live poliovirus vaccine in warm climate. Bull WHO 51: 333–347Google Scholar
  9. 9.
    Expanded Programme on Immunization. Poliomyelitis in 1986, 1987 and 1988 (Part 1). (1989) Wkly Epidemiol Record 64: 273–279Google Scholar
  10. 10.
    Expanded Programme on Immunization. Poliomyelitis in 1986, 1987 and 1988 (Part 2). (1989) Wkly Epidemiol Record 37: 281–285Google Scholar
  11. 11.
    Faden H, Duffy L. (1992) Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines AJDC 146: 1320–1323PubMedGoogle Scholar
  12. 12.
    Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL (1990) Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses. J Infect Dis 162: 1291–1297PubMedCrossRefGoogle Scholar
  13. 13.
    Ghendon YZ, Sanakoyeva LL (1961) Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin’s strains) in persons after naturally and experimentally acquired immunity. Acta Virol 5: 265–273Google Scholar
  14. 14.
    Glezen WP, Lamb GA, Beiden EA, Chin TDY (1966) Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 83:224–237PubMedGoogle Scholar
  15. 15.
    Grenier B, Hamza B, Xueref BC, Viarme F, Roumaintzeff M (1984) Seroimmunity following vaccination in infants by an inactivated poliovirus vaccine prepared on vero cells. Rev Infect Dis 6: S545-547Google Scholar
  16. 16.
    HenryJL, Jaikaran ES (1966) A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg Camb 64: 105–120PubMedCrossRefGoogle Scholar
  17. 17.
    Horstmann DM, Opton EM, Klemperen R, Llado B, Vignic AJ (1964) Viremia in infants vaccinated with oral poliovirus vaccine (Sabin). Am J Hygiene 79:47–63Google Scholar
  18. 18.
    Hovi T, Huovilainen A, Kuronen T, Poyry T, Salama N, Cantell K, Kinnunen E, Lapinleimu K, Roivainen M, Stenvik M (1986) Outbreak of paralytic poliomyelitis in Finland: Widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. The Lancet II: 1427–1432CrossRefGoogle Scholar
  19. 19.
    John TJ, Christopher S (1975) Oral polio vaccination of children in the tropics. III. Intercurrent enterovirus infections, vaccine virus take, and antibody response. Am J Epidemiol 102: 422–428PubMedGoogle Scholar
  20. 20.
    Kohara M, Abe S, Kamatsu T, Tago K, Arita M, Nomoto A (1988) A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain. J Virol 62: 2828–2835PubMedGoogle Scholar
  21. 21.
    Lasch EE, Abed Y, Abdulla K, Tibbi AG, Marcus O, El Massri MR, Gerichter CB, Melnick JL (1984) Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 6: 2; 467–470CrossRefGoogle Scholar
  22. 22.
    Lepow ML, Warren RJ, Gray N, Ingram VG, Robbins FC (1961) Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants. N Engl J Med 264: 1071–1078PubMedCrossRefGoogle Scholar
  23. 23.
    McBean AM, Modlin JF (1987) Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 6: 881–887PubMedCrossRefGoogle Scholar
  24. 24.
    McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R, The Field Staff and Coordinating Committee (1988) Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Amer J Epidemiol 128: 615–628Google Scholar
  25. 25.
    Minor PD ,Dunn G (1988) The effect of sequences in the 5’ non-coding region on the replication of polioviruses in the human gut. J Gen Virol 69: 1091–1096PubMedCrossRefGoogle Scholar
  26. 26.
    Modlin JF, Onorato IM, McBean AM, Albrecht P ,Thoms ML, Nerhood L, Bernier R (1990) The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine. AJDC 144: 480–484PubMedGoogle Scholar
  27. 27.
    Murray MG, Kuhn RJ, Arita M, Kawamura N, Nomoto A, Wimmer E (1988) Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc Natl Acad Sci USA 85: 3203–3207PubMedCrossRefGoogle Scholar
  28. 28.
    Ogra PL (1984) Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis 6: S361–368PubMedCrossRefGoogle Scholar
  29. 29.
    Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD (1991) Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164: 191–194PubMedCrossRefGoogle Scholar
  30. 30.
    Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH (1991) Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 163: 1–6PubMedCrossRefGoogle Scholar
  31. 31.
    Pan American Health Organization (1986) Polio incidence rises in Brazil’s northeast. EPI News 8:4–5Google Scholar
  32. 32.
    Patriarca PA, Wright PF, John TJ (1991) Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Rev Infect Dis 13:926–939PubMedCrossRefGoogle Scholar
  33. 33.
    Raconiello VR (1988) Poliovirus neurovirulence. Adv Virus Res 34: 217–246CrossRefGoogle Scholar
  34. 34.
    Retrospective assessment of vaccination coverage among school-aged children -selected U.S. cities, 1991 MMWR 41(6): 103–107Google Scholar
  35. 35.
    Robertson SE, Drucker JA, Farbe-Teste B, D’Diaye M, Traverso HP, Rovira EZ, Sow A, Sy MTA, Diouf F. (1988) Clinical efficacy of a new ,enhanced-potency, inactivated poliovirus vaccine. The Lancet 1: 897–900CrossRefGoogle Scholar
  36. 36.
    Roivainen M, Hovi T (1987) Intestinal trypsin can significantly modify antigenic prop erties of polioviruses: Implications for the use of inactivated poliovirus vaccine. J Virol 61:3749–3753PubMedGoogle Scholar
  37. 37.
    Roivainen M, Hovi T (1988) Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin. J Virol 62: 3536–3539PubMedGoogle Scholar
  38. 38.
    Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ (1985) Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. AJDC 139: 977–980PubMedGoogle Scholar
  39. 39.
    Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14: 568–579PubMedCrossRefGoogle Scholar
  40. 40.
    van Wezel AL, van Stenis G, Hannik CA (1978). New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Div Biol Stand 41: 159–168Google Scholar
  41. 41.
    von Magnus H, Petersen I (1984). Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 6: 471–474CrossRefGoogle Scholar
  42. 42.
    Westrop GD, Wareham KA, Evans DMA, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW (1989) Genetic basis for attenuation of the Sabin type 3 oral poliovirus vaccines. J Virol 63: 1338–1344PubMedGoogle Scholar
  43. 43.
    Wright PF, Kim-Farley RJ ,de Quadros CA, Robertson SE, Scott RM, Ward NA, Henderson RH (1991) Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 325: 1772–1779CrossRefGoogle Scholar
  44. 44.
    Zhaori G, Sun M, Faden H, Ogra PL (1989) Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 159: 1018–1024PubMedCrossRefGoogle Scholar
  45. 45.
    Zhaori G, Sun M, Ogra PL (1988) Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J Infect Dis 158: 160–165PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • H. Faden
    • 1
  1. 1.Division of Infectious Diseases, Department of PediatricsState University of New York, School of Medicine at Buffalo and the Children’s Hospital of BuffaloBuffaloUSA

Personalised recommendations